Global Prostate Cancer Medicine Market Growth (Status and Outlook) 2025-2031

According to this study, the global Prostate Cancer Medicine market size will reach US$ million by 2031.

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. This cancer develops slowly, with no early detectable symptoms for many years. The precise cause of prostate cancer is unknown; however, factors such as obesity, high calcium diet, lack of exercise, ethnicity (African American men), and old age contribute to its occurrence.

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

LPI (LP Information)' newest research report, the “Prostate Cancer Medicine Industry Forecast” looks at past sales and reviews total world Prostate Cancer Medicine sales in 2024, providing a comprehensive analysis by region and market sector of projected Prostate Cancer Medicine sales for 2025 through 2031. With Prostate Cancer Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prostate Cancer Medicine industry.

This Insight Report provides a comprehensive analysis of the global Prostate Cancer Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Prostate Cancer Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Prostate Cancer Medicine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prostate Cancer Medicine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prostate Cancer Medicine.

This report presents a comprehensive overview, market shares, and growth opportunities of Prostate Cancer Medicine market by product type, application, key players and key regions and countries.

Segmentation by Type:
LHRH Antagonists
LHRH Analogs
Antiandrogens
Pipeline Drugs for Hormonal Therapy

Segmentation by Application:
Age Below 55
Age 55-75
Age Above 75

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca plc
Active Biotech
Bristol Myers-Squibb
Teva Pharmaceuticals Industries Ltd.
Johnson & Johnson
Pfizer Inc.
Bayer AG
Abbott Laboratories
Astellas Pharma Inc.
Roche Holding AG

Please note: The report will take approximately 2 business days to prepare and deliver. Show more